Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Third Quarter of 2006Decision ResourcesDecember 15, 2006 22 Pages - SKU: DECR1399806 |
|
Introduction In the major pharmaceutical markets, efforts to curb drug expenditures and to improve patient access to medications were the driving forces in the third quarter of 2006. In the United States, adjustments to the Medicare Part D prescription drug benefi t were announced. European governments focused on cost-containment measures and increasing generics usage, while the Japanese government continued its deliberations on whether to introduce annual price revisions. Questions Answered in This Spectrum Report Price sensitivity is growing in the world's major pharmaceutical markets. In an increasingly hostile environment, pharmaceutical companies will need to think creatively about their pricing strategies in each market. What future pricing strategies should companies consider in the U.S. and European markets? How have Amgen, Genentech, and GlaxoSmithKline responded to increasing price sensitivity? In all the major pharmaceutical markets, increasing the use of generic drugs will be a priority for payers. Which countries have relatively immature generics markets, and how will government intervention stimulate their growth? What factors will fuel the growth of the generics market in the United States? Governments in most of the major pharmaceutical markets have long used their powers to reduce drug prices. How will recent cost-containment measures in Germany, Italy, and Spain affect the pharmaceutical markets in those countries? How is the German government proposing to overhaul its health care system, and what reforms will target the pharmaceutical industry? Scope
|
Additional Information
Companies Mentioned in This Spectrum Report
- Abbott Laboratories
- Amgen
- Apotex
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Elan
- Eli Lilly
- Genentech
- GlaxoSmithKline
- Link Pharmaceuticals
- Merck KGaA
- Pfi zer
- Roche
- Sanofi -Aventis
- Schering-Plough
- Scios
Related Markets
- Insurance & Managed Care
- General Insurance & Managed Care
- Pharmaceuticals
- General Pharmaceuticals
- Regulation & Policy
- Prescription Drugs
- Pricing
Pricing Reports
- Pricing and Reimbursement in Generics - European Austerity Measures and Healthcare Cost Containment Puts Innovation-Driven Pharma Companies under Pressure
- Pricing and Reimbursement in Russia - Big Pharma Take Advantage of Reimbursement for Costly Drugs Through the DLO’s Seven Nosologies Program
- Pricing and Reimbursement of the Healthcare System in India - Low Levels of Drug Reimbursement Lead to a High Out-Of-Pocket Expenditure
- The Royalty Rate Report 2012: A Comprehensive Assessment of Valuation in the Pharmaceutical Sector
- Pharmaceutical Pricing Strategies – Changing Approaches to Meet Challenging Times
